BioWorld

April 25, 2003

View Archived Issues

Genzyme Wins FDA Approval For Fabry's Disease Treatment

Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today) Read More

High Revenues Drive Earnings Growth At Biotech Bellwethers

Read More

Coated Magnetic Beads Take Over Dendritic Cell's Flagging Down Of Invasive Antigens For Destruction

Read More

FDA Clears Path For Phase III; NeoRx Stock Soars On News

Read More

Correction

Read More

Thompson Pushes Administration Initiatives In Science Forum Talk

Read More

Other News To Note

Read More